Gene Targeting Techniques for Huntington's Disease by Fields, Eric et al.
Gene Targeting Techniques for Huntington’s Disease
Team CHANGE
Eric Fields, Erik Vaughan, Deepika Tripu, Isabelle Lim, Katherine Shrout, Jessica Conway, 
Nicole Salib, Yubin Lee, Akash Dhamsania, Michael Jacobsen, Ashley Woo








○ Targets specific mRNA 
sequence 
○ About 20-24 base pair 
specificity
● miRNA based
○ Targets  3’-UTR
○ About 22 base pair 
specificity
● ASO based
○ DNA molecule that targets 
RNA sequence
○ About 18-30 base pair 
specificity
● CRISPR based
○ Edits DNA sequence
○ Requires gRNA and PAM 
sequence match (~20 base 
pairs and 3 base pairs)
● Target endogenous SNPs
● Established HD haplogroups
● Fibroblast (skin) cells
● Neural stem cells
● TruHD immortalized 
fibroblast cell line 
Our future direction seeks to utilize novel gene editing 
technique, prime editing, to target the mHTT gene by 
inserting stop codons that will prematurely terminate the 
production of mHTT protein, which may effectively reduce 
the symptoms of Huntington’s. This technique only nicks one 
DNA site to insert its desired sequence rather than the two 
sites that CRISPR-Cas9 requires, which significantly 
reduces off-targeting effects associated with CRISPR and 
potentially increases gene targeting efficiency as compared 
to already existing methods (Anzalone et al., 2019). This 
approach would ideally be combined with SNPs in order to 
achieve allele specificity, but with limited time and funds, the 
approach may instead be applied in a non-allele specific 
manner. In terms of general Huntington’s research, there are 
a number of ongoing clinical trials for the methods discussed 
so far and the results of those trials are being awaited. 
There are numerous studies in various stages of clinical 
trials and are available at clinicaltrials.gov.
Introduction Results
The gene targeting techniques showed notable promise for 
the reduction of mHTT in cells. Both RNA targeting and DNA 
targeting methods were able to demonstrate improved 
behavior in non-human animal models. RNA targeting 
approaches have been more thoroughly researched, but with 
the more recent advances with CRISPR technology, DNA 
targeting approaches may become more advantageous for 
their ability to permanently edit the expression of mHTT. The 
risk of these techniques largely is in the potential for off 
targeting, which presently is not negligible. Some 
approaches have directly targeted the CAG repeat, but with 
the presence of other genes with CAG repeats in the 
genome, this is likely risky. Targeting of SNPs have been 
shown to allow for a large degree of allele specificity so as to 
avoid targeting the healthy allele. Although SNP haplogroups 
have been established, individual screening of SNPs for 
patients would be needed with this approach.
Huntington’s disease (HD) is an autosomal neurodegenerative 
disorder caused by extended trinucleotide CAG repetition in the 
HTT gene. 
This mutation is mostly associated with both neurological and 
physical symptoms. The main cause of HD symptoms is due to 
aggregation and accumulation of mutant HTT (mHTT) proteins in 
neurons. In this poster, we review multiple approaches targeting 
DNA and RNA to reduce mHTT expression. These approaches 
are categorized into non-allele-specific silencing and 
allele-specific-silencing using SNPs and haplogroup analysis, and 
the possible limitations of targeting mHTT is also discussed. 
RNA targeting
● ASO approach by Datson et. 
al targeting CAG repeats 
resulted in a reduction of 
mHTT transcripts by 83% 
and wild-type transcripts by 
43%
○ Other CAG repeat genes 
had reduced transcription, 
displaying off targeting
○ However, neurological 
function was restored in 
mice
● Artificial viral-mediated 
miRNA designed by 
Boudreau et al. resulted in 
improved behavior and 
survival in mice, also finding 
mammals can tolerate up to 
75% decrease in wild type 
HTT expression
● Another approach using an 
AAV that degraded HTT with 
siRNA saw reduction in 
levels by 40% and improved 
behavior (Stanek et al., 
2014)
Non allele-specific editing (Xu, 2017)
● HD-patient derived iPSCs were transfected with a vector containing the sgRNA and 
cas9 variant
● Normal karyotype and retained pluripotency
● Differentiated into functional GABAergic neurons that had no evidence of HTT 
aggregates
● Rescued ability of hiPSCs from HD to form neural rosettes and functional 
mitochondria
Allele specific gene editing using SNPs (Shin et al., 2016)
● Excised the promoter, transcriptional start site, and CAG repeats while leaving the 
healthy allele unaffected
● 6 SNPs upstream of HTT exon 1 were identified that created or destroyed a PAM 
sequence on mutant allele
● 80% (n=11) of HTT fibroblasts tested were heterozygous for rs2857935, an SNP in 
the promoter region that destroys  a PAM sequence
● Effectively used as a targeBy utilizing the aforementioned 
genetic technology, our team aims to develop a 
method to correct HD using the patient’s own 
somatic cells. The use of autologous cells 
would reduce the risk of immune rejection and 
ultimately disrupt the process of genetic 
correction. If successful, this would have a 
revolutionary effect on patients and families 
affected by HD. As a team, any innovative 
research we can contribute to the scientific 
community would be immensely rewarding and 
allow greater progress toward curing this 
devastating disease. 
● t to delete promoter on mutant allele while leaving healthy allele unaffected
DNA targeting
Allele specific (Shin et al 2016)
● Excised the promoter, 
transcriptional start site, and 
CAG repeats while leaving 
the healthy allele unaffected
● 6 SNPs upstream of HTT 
exon 1 were identified that 
created or destroyed a PAM 
sequence on mutant allele
● 80% (n=11) of HTT 
fibroblasts tested were 
heterozygous for rs2857935, 
an SNP in the promoter 
region that destroys  a PAM 
sequence
● Effectively used as a target 
to delete promoter on 
mutant allele while leaving 
healthy allele unaffected
Non allele-specific (Xu, 2017)
● HD-patient derived iPSCs 
were transfected with a 
vector containing the sgRNA 
and cas9 variant
● Normal karyotype and 
retained pluripotency
● Differentiated into functional 
GABAergic neurons that had 
no evidence of HTT 
aggregates
● Rescued ability of hiPSCs 
from HD to form neural 
rosettes and functional 
mitochondria
